Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica ›› 2011, Vol. 33 ›› Issue (5): 582-586.doi: 10.3881/j.issn.1000-503X.2011.05.020

• Review Articles • Previous Articles     Next Articles

Role of 5α-reductase Inhibitors in the Chemoprevention of Prostate Cancer

AN Chao, XU Tao, WANG Xiao-feng   

  1. Department of Urology, Peking University People's Hospital, Beijing 100044, China
  • Received:2010-09-27 Revised:2011-10-28 Online:2011-10-28 Published:2011-10-28
  • Contact: XU Tao E-mail:xutao@medmail.com.cn

Abstract: Prostate cancer is one of the most common visceral malignancies in human. In recent years, its incidence has dramatically increased in China. 5α-reductase inhibitors can block the biological effects of dihydrotestesterone by restraining the transformation from testosterone to dihydrotestesterone, and therefore can be used for the chemoprevention of prostate cancer. Two large clinical trials on the chemoprevention of prostate cancer (the Prostate Cancer Prevention Trial and the Reduction by Dutasteride of Prostate Cancer Events) were completed in 2003 and 2008, respectively, bringing the global interests on this topic. However, the interpretations of these two trials and the possible recommendations on clinical applications remain controversial.

Key words: prostate cancer, 5α-reductase inhibitors, Prostate Cancer Prevention Trial, Reduction by Dutasteride of Prostate Cancer Events, chemoprevention

CLC Number: